Intensity Therapeutics advances innovative cancer treatment in collaboration with SAKK
Intensity Therapeutics, Inc., a leading biotechnology company, has embarked on a pivotal collaboration with The Swiss Group for Clinical Cancer Research (SAKK) to launch a Phase 2 clinical trial, dubbed the INVINCIBLE-4 Study. This trial aims to explore the effectiveness of the innovative cancer treatment INT230-6 in early-stage triple-negative breast cancer (TNBC). The study will […]